Sudo Biosciences Secures $116 Million in Series B Funding Round
Sudo Biosciences, a biopharmaceutical company dedicated to crafting top-tier precision TYK2 (tyrosine kinase 2) inhibitors, has announced the successful conclusion of a $116 million Series B funding round. The round was co-led by Enavate Sciences and TPG, with investment from TPG Life Sciences Innovations and The Rise Fund, alongside Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, and Eventide Asset Management, as well as existing investors Frazier Life Sciences and Velosity Capital. Since its inception in 2020, the company has amassed a total of $157 million in funding.
The Series B financing will fuel the advancement of two investigational TYK2 candidates into clinical trials in the coming year. Among these, Sudo’s CNS program stands out as a potential pioneer, offering a breakthrough brain-penetrant TYK2 inhibitor with the promise to revolutionize treatment for both relapsing and progressive forms of multiple sclerosis, along with neurodegenerative disorders like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Additionally, Sudo is actively developing a groundbreaking topical TYK2 inhibitor for conditions such as psoriasis and other immune-mediated dermatologic ailments.
Scott Byrd, CEO of Sudo Biosciences, expressed gratitude for the support from premier life science investors, affirming that the financing positions the company to advance its pipeline and fulfill its mission of enhancing care for individuals affected by multiple sclerosis, psoriasis, and other severe autoimmune and neurologic conditions.
Enavate Sciences’ Executive Vice President of Commercialization, Edd Fleming, cited Sudo’s scientific excellence, seasoned leadership, and the clinical potential of its TYK2 inhibitors as key factors driving their interest in the company. He emphasized the urgent need for improved treatments for severe neurologic diseases like progressive forms of MS, Alzheimer’s, and ALS, expressing confidence in Sudo’s CNS program to address these unmet needs effectively.
Shinichiro Fuse, PhD, Business Unit Partner at TPG Life Sciences Innovations, underscored the exciting partnership with Sudo, highlighting the therapeutic potential of TYK2 inhibition in tackling neuroinflammation and autoimmune diseases. He praised the promising pre-clinical data supporting Sudo’s CNS and dermatology TYK2 programs, affirming TYK2’s viability as a target in these critical therapeutic areas.
